Intellia Therapeutics (NTLA)Bridgewater Associates exited its position 223K shares

223K

Prior-quarter shares · no longer reported

Holdings as of

Mar 31, 2026

Filed

May 15, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Apr 7, 2026Company filing · Form 8-K · Bylaws or charterChanged its bylaws, charter or fiscal year
2. Apr 27, 2026Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results
3. May 11, 2026Company filing · Form 8-K · ResultsReported its results

What came next

1. Aug 6, 2026Company filing · Form 8-K · ResultsReported its results
2. Sep 4, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Intellia Therapeutics

For Intellia Therapeutics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its NTLA page.

How this filing works

• SEC Form 13F

Other disclosures at Intellia Therapeutics

• SEC Form 4Oct 7, 2026
• SEC Form 144Oct 5, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 13, 2026
• SEC Form 13F-HRMay 12, 2026

Everything OQRO holds on this company is on its NTLA page.